Results 1 to 3 of 3

Thread: I got this from an MS news site. The top 15 MS research articles of 2015

  1. #1
    Distinguished Community Member Lazarus's Avatar
    Join Date
    Oct 2006
    western MA
    Blog Entries

    Default I got this from an MS news site. The top 15 MS research articles of 2015

    As 2015 comes to an end, here are the year’s 10 articles most widely read by Multiple Sclerosis News Today readers, each with a brief summary of the developments that made them of such interest to MS patients, caregivers and their loved ones.

    No. 10 – “Vaccine Against MS Being Developed at Baylor Institute for Immunology Research”

    This study reports the development of a potential MS vaccine by researchers at the Baylor Institute for Immunology Research in Texas. The vaccine is based on blood-derived stem cells that are engineered to become dendritic cells, which are then sensitized with immunogenic proteins known to play a role in MS. Through vaccination, these dendritic cells may prime specific cells of the immune system to attack the immunogenic proteins within the body, suppressing deleterious inflammatory responses.

    No. 9 – “Ocrelizumab: Could Genentech/Roche’s Experimental Drug Be the First Effective Progressive MS Therapy?”

    Three pivotal Phase 3 clinical trials assessing the experimental MS therapy ocrelizumab (Genentech, Roche) revealed that the drug can decrease disease activity and progression in patients with relapsing MS and, remarkably, also in patients with primary progressive MS (PPMS), a debilitating form of the disease with no approved treatments. Ocrelizumab is the first investigational medicine seen to significantly reduce disability progression in relapsing MS and PPMS. Roche is planning to seek marketing authorization for ocrelizumab in both indications.

    No. 8 – “A Step Toward Multiple Sclerosis Treatment? Phase 2 ANTI-LINGO-1 Results Announced”

    Anti-LINGO-1 is a medication that restores myelin, the protective sheath covering neurons that is destroyed in MS. Anti-LINGO-1 was shown to help in remyelination and in the repair of the damaged visual system in patients with relapsing MS, specifically those with a condition called acute optic neuritis that is characterized by injury to the optic nerve. Future studies should assess the anti-LINGO-1’s clinical potential in restoring myelin and reducing MS symptoms.

    No. 7 – “Mitochondria May Play a Role in MS Development and Progression”

    This study suggests that mitochondrial defects, as well as mitochondrial structural and functional changes, may contribute to MS disease development and progression. Researchers believe abnormalities in mitochondrial dynamics impact cellular pathways such as inflammation and demyelination, ultimately contributing to MS pathology. A few therapeutic approaches for MS treatment by targeting the mitochondria are discussed, namely mitoxantrone and mitochondria-targeted antioxidants such as MitoQ.

    No. 6 – “Multiple Sclerosis Treatments Benefit From Discovery of New Inflammatory Molecule”

    A study reporting on the discovery of a molecule called MCC950 that could play a pivotal role in inflammatorydiseases like MS. MCC950 was found to suppress the “NLRP3 inflammasome,” a key process in inflammatory diseases. Future studies in humans are needed, however, to confirm that this molecule could represent a therapeutic approach for MS.

    No. 5 – “Increased R&D Focus On PoNS Neuromodulation Therapy Device For People With MS; Other Neurological Conditions”

    An article reporting the increasing interest in the “PoNs” stimulator, the first non-invasive means for delivering neurostimulation through the oral cavity. The concept behind the device is that lingual stimulation combined with therapeutic exercise may enable the brain to form new neural pathways and recover motor functions like balance and movement in MS and other neurological conditions.

    No. 4 – “Three Years After Stem Cell Transplant Therapy Most MS Patient Subjects Still In Remission”

    This report details how patients with active relapsing-remitting MS (RRMS), who had received an experimental high-dose immunosuppressive therapy (HDIT) followed by a transplant of their own hematopoietic stem cells, remained in sustained remission and exhibited improvements in neurological function and quality of life three years after the treatment. The results are a three-year interim analysis of the Phase 2 clinical trial HALT-MS (Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis). Researchers believe that such stem cell therapy represents a potential therapeutic option, particularly for MS patients unresponsive to conventional immunotherapy.

    No. 3 – “Rare Brain Infection Death Spurs FDA To Update Warning Label for MS Drug”

    The article focuses on the U.S. Food and Drug Administration (FDA) warning to the general public and healthcare providers that Tecfidera (dimethyl fumarate, Biogen Idec), one of the leading MS medications, could be associated with the development of progressive multifocal leukoencephalopathy (PML), a rare and serious brain infection caused by the John Cunningham virus. The FDA required Biogen to include PML-related death on the drug’s label after the death of one MS patient under Tecfidera treatment.

    No. 2 – “New Multiple Sclerosis Drug May Repair Nerve Demyelination”

    As reported in article No. 8, anti-LINGO-1 is a new treatment option for MS that may directly address the need for protecting neurons and promote remyelination. Apart from repair of the damaged visual system, the therapeutic potential of anti-LINGO-1 in slowing MS progression and improvement of disease symptoms is also being assessed. Phase 1 clinical trials have shown that the therapy to be safe, with no report of serious adverse effects. Phase 2 clinical trials on anti-LINGO-1 are currently being conducted to confirm if it can indeed restore myelination along with physical and cognitive function.

    No. 1 – “Multiple Sclerosis Could be Treated with a Surprising Medication”

    The article focuses on a study from the State University of New York at Buffalo suggesting that an approved medication for bladder problems, called solifenacin, might help to treat MS. Researchers found that solifenacin can act on oligodendrocytes, cells that produce myelin, to promote nerve remyelination.

    More welcome news and discoveries in MS are expected in 2016, especially regarding the promising drugs ocrelizumab and anti-LINGO-1, the PoNs device, and therapeutic approaches based on stem cell therapies. Multiple Sclerosis News Today hopes these new developments will ultimately contribute to improvements in the lives of patients living with MS.

    Be the kind of woman that when your feet hit the floor each morning the devil says:"Oh Crap, She's up!"

  2. #2
    Distinguished Community Member Sunshine's Avatar
    Join Date
    Oct 2006


    Thanks for the great summaries,

  3. The following 6 users say "thanks"

  4. #3
    Distinguished Community Member SuzE-Q's Avatar
    Join Date
    Nov 2006


    Thanks, Linda!

    I missed hearing about some of these before, so I appreciate hearing what's buzzing about! Interesting to see what's interesting others!

  5. The following 4 users say "thanks"

Similar Threads

  1. Ectrims 2015
    By SuzE-Q in forum Multiple Sclerosis
    Replies: 3
    Last Post: 10-12-2015, 11:26 PM
  2. Two interesting articles
    By Ted-T in forum Epilepsy
    Replies: 0
    Last Post: 06-11-2015, 11:30 AM
  3. I copied this from another MS site...important good MS news
    By Lazarus in forum Multiple Sclerosis
    Replies: 3
    Last Post: 04-14-2015, 04:33 PM
  4. MRI: How long before I can assume "no news is good news?"
    By Alesis in forum Headache & Migraine
    Replies: 4
    Last Post: 01-02-2013, 09:23 AM
  5. Dr Gray..published/informative articles relating to spinal leaks..For my appeal.
    By hemyinspain in forum Cerebrospinal Fluid (CSF) Leak
    Replies: 2
    Last Post: 11-15-2011, 06:42 AM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts

BTC Inc's Disclaimer and Privacy Policy

The material on this site is for information & support purposes only, and is not a substitute for medical advice provided by a licensed health care provider. Always consult your doctor before trying anything that you find online.